Quantitative proteome profiling of human myoma and myometrium tissue reveals kinase expression signatures with potential for therapeutic intervention

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 356-364

  Lemeer, Simone ^a   Gholami, Amin Moghaddas ^a   Wu, Zhixiang ^a   Kuster, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomedicine; DDR1; Label free quantification; Leiomyoma; MS

Indexed keywords

CASEIN KINASE II; COLLAGEN; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; CYCLIN DEPENDENT KINASE 5; EPHRIN RECEPTOR B1; KINOME; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEOME; RECEPTOR TYROSINE KINASE DDR1; UNCLASSIFIED DRUG; DDR1 PROTEIN, HUMAN; PROTEIN KINASE;

AREA UNDER THE CURVE; ARTICLE; DRUG TARGETING; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; LEIOMYOMA; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; UTERUS MYOMA; ANIMAL; PATHOLOGY; RAT; TANDEM MASS SPECTROMETRY; UTERUS CANCER;

ANIMALS; FEMALE; HUMANS; LEIOMYOMA; MYOMETRIUM; PROTEIN KINASES; PROTEOME; PROTEOMICS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; TANDEM MASS SPECTROMETRY; UTERINE NEOPLASMS;

EID: 84921358594     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400213     Document Type: Article

References (36)

1. Walker, C. L., Stewart, E. A., Uterine fibroids: the elephant in the room. Science 2005, 308, 1589-1592.
2. Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D., Schectman, J. M., High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obst. Gynecol. 2003, 188, 100-107.
3. Stewart, E. A., Uterine fibroids. Lancet 2001, 357, 293-298.
4. Bulun, S. E., Uterine fibroids. New Engl. J. Med. 2013, 369, 1344-1355.
5. Zaitseva, M., Vollenhoven, B. J., Rogers, P. A., Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium. Mol. Hum. Reprod. 2007, 13, 577-585.
6. Maybin, J. A., Critchley, H. O., Jabbour, H. N., Inflammatory pathways in endometrial disorders. Mol. Cell. Endocrinol. 2011, 335, 42-51.
7. Blake, R. E., Leiomyomata uteri: hormonal and molecular determinants of growth. J. Natl. Med. Assoc. 2007, 99, 1170-1184.
8. Arslan, A. A., Gold, L. I., Mittal, K., Suen, T. C. et al., Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum. Reprod. 2005, 20, 852-863.
9. Makinen, N., Mehine, M., Tolvanen, J., Kaasinen, E. et al., MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011, 334, 252-255.
10. Turunen, M., Spaeth, J. M., Keskitalo, S., Park, M. J. et al., Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep. 2014, 7, 654-660.
11. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S. et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 1035-1044.
12. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367-1372.
13. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A. et al., Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011, 10, 1794-1805.
14. Huber, W., von Heydebreck, A., Sultmann, H., Poustka, A., Vingron, M., Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18 (Suppl 1), S96-S104.
15. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B. et al., Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5, R80.
16. Smyth, G. K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3, Article3.
17. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995, 57, 289-300.
18. Pepe, M. S., Longton, G., Anderson, G. L., Schummer, M., Selecting differentially expressed genes from microarray experiments. Biometrics 2003, 59, 133-142.
19. Pepe, M. S., Cai, T., Longton, G., Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 2006, 62, 221-229.
20. Schirle, M., Heurtier, M. A., Kuster, B., Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 2003, 2, 1297-1305.
21. Ciarmela, P., Islam, M. S., Reis, F. M., Gray, P. C. et al., Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update 2011, 17, 772-790.
22. Norian, J. M., Malik, M., Parker, C. Y., Joseph, D. et al., Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod. Sci. 2009, 16, 1153-1164.
23. Luo, X., Ding, L., Xu, J., Chegini, N., Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005, 146, 1097-1118.
24. Kovacs, K. A., Lengyel, F., Wilhelm, F., Vertes, Z. et al., Involvement of FKHR (FOXO1) transcription factor in human uterus leiomyoma growth. Fert. Sterility 2010, 94, 1491-1495.
25. Lattuada, D., Vigano, P., Mangioni, S., Sassone, J. et al., Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasome-mediated degradation and an alteration of its transcriptional activity. Mol. Endocrinol. 2007, 21, 602-612.
26. Yoon, S. Y., Lee, Y., Kim, J. H., Chung, A. S. et al., Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem. Biophys. Res. Comm. 2005, 326, 7-17.
27. Tsai, F. C., Liu, W. M., Pai, M. H., Hsieh, M. S. et al., Downregulation of the integrin alpha(v) signaling pathway in uterine leiomyomas. Gynecol. Obst. Invest. 2011, 71, 129-135.
28. Kim, J. J., Sefton, E. C., The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol. Cell. Endocrinol. 2012, 358, 223-231.
29. Crabtree, J. S., Jelinsky, S. A., Harris, H. A., Choe, S. E. et al., Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res. 2009, 69, 6171-6178.
30. Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N. et al., Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149, 307-321.
31. Contreras-Vallejos, E., Utreras, E., Gonzalez-Billault, C., Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell. Signal. 2012, 24, 44-52.
32. Guerrot, D., Kerroch, M., Placier, S., Vandermeersch, S. et al., Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am. J. Pathol. 2011, 179, 83-91.
33. Avivi-Green, C., Singal, M., Vogel, W. F., Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am. J. Resp. Crit. Care Med. 2006, 174, 420-427.
34. Ruiz, P. A., Jarai, G., Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J. Biol. Chem. 2011, 286, 12912-12923.
35. Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J. et al., Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114, 1308-1316.
36. Drosch, M., Bullerdiek, J., Zollner, T. M., Prinz, F. et al., A novel mouse model that closely mimics human uterine leiomyomas. Fert. Sterility 2013, 99, 927-935, e926.